Changes in Hong Kong stocks | Hebo Pharmaceutical-B (02142) rose more than 4%, revenue in the first half of the year increased by more than 20% year-on-year, and continued BD verified the company's platform value

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose more than 4%. As of press release, it had risen 4.31% to HK$15.02, with a turnover of HK$115 million.

According to the news, recently, Hebo Pharmaceutical-B announced interim results for the six months ended June 30, 2026, with revenue of US$122 million, an increase of 20.9% over the previous year. According to the announcement, total revenue during the reporting period was US$122 million, an increase of 20.9% over US$101 million in the first half of 2025. Molecular licensing and cooperation revenue increased from US$93.7 million to US$113 million, mainly due to continued strategic cooperation with leading global pharmaceutical companies and external licensing and cooperation for innovative products. Meanwhile, revenue from research services and technology licensing fees increased 23.8% from US$7.6 million to US$9.4 million.

According to the CICC Research Report, Hebo Pharmaceutical-B's performance in the first half of the year exceeded expectations, mainly due to CTLA-4 overseas licensing to increase revenue. CICC pointed out that the company is shifting from single product licensing to parallel platform cooperation, product licensing and joint development. BD continues to verify the company's platform value, but cooperation still accounts for more than 90% of revenue, and performance may fluctuate with the pace of transactions and revenue confirmation. Furthermore, LET003, the company's first AI-driven weight loss candidate, was used in combination with simeglutide to show the potential to enhance fat loss and protect lean body mass in preclinical studies. The company expects to submit IND on 3Q26.